Table 1 Baseline characteristics of patient cohorts and control
Disease | N | Age (mean, sd) | Mortality (%) | Sex (male, %) | Race (W/AA/NA/A, %) | Specimen |
|---|---|---|---|---|---|---|
First Study Cohort (IH-ELISA assay) | ||||||
 Trauma | 66 | 25 ± 5.8 | 10.4 | 100.0 | NA | plasma |
 Lower | 31 | 24 ± 4.8 | 6.5 | 100 | NA | plasma |
 Upper | 20 | 25 ± 6.7 | 20 | 100 | NA | plasma |
 Combined | 13 | 22 ± 8.4 | 7.6 | 100 | NA | plasma |
 ARDS | 248 | 50.3 ± 14.3 | 21.7 | 51.2 | 73.7, 18.5, 1.2, 0.4 | plasma |
 Sepsis | 123 | 56.7 ± 16.2 | 16.2 | 48.4 | 66.4, 33.4, 0.75, 0 | plasma |
 Sepsis only | 55 | 54.5 ± 17.7 | 7.2 | 54.5 | 58.8, 40, 1.8, 0 | plasma |
 Septic shock | 68 | 59.5 ± 14.5 | 23.5 | 41.2 | 72, 28, 0, 0 | plasma |
 Sepsis (SK) | 100 | 66.5 ± 13.5 | 19 | 62.0 | 0, 0, 0, 100 | serum |
 Sepsis only | 20 | 60.3 ± 15.2 | 5 | 80.0 | 0, 0, 0, 101 | serum |
 Septic shock | 80 | 66.2 ± 12.7 | 21.2 | 58.7 | 0, 0, 0, 102 | serum |
 Pancreatitis | 59 | 51 ± 18.4 | 3.3 | 45.8 | 88.1, 6.7, 7.1, 0 | serum |
 Mild | 29 | 50.8 ± 20.2 | 0 | 37.9 | 82.7, 10.3, 0, 0 | serum |
 Moderate | 14 | 45.8 ± 16.6 | 0 | 42.9 | 85.7, 7.1, 7.1, 0 | serum |
 Severe | 16 | 56.3 ± 15.2 | 12.5 | 62.5 | 100, 0, 0, 0 | serum |
 Healthy controls | 70 | 62 ± 14 | 0 | 70 | 82.8, 10, 1.4, 0 | plasma |
 Healthy controls | 31 | 57.5 ± 20.9 | 0 | 32.3 | 83.9, 9.7, 3.2, 0 | serum |
Second Study Cohort (MSD assay) | ||||||
 ARDS | 100 | 55.4 ± 15.3 | 37 | 52 | 88, 3, 7, 1 | plasma |
 Sepsis | 98 | 55.5 ± 17.6 | 14 | 48 | 84, 13, 1, 1 | plasma |
 Healthy controls | 78 | 55.2 ± 16.75 | 0 | 57.7 | 83, 10.2, 1, 0 | plasma |